GE Healthcare has received FDA clearance of Q.Freeze, a PET/CT quantitative imaging technology designed for treatment evaluation earlier in a patient’s cancer treatment.
Q.Freeze combines the quantitative benefits of 4D phase-matched PET/CT imaging, MotionMatch, into one static image, according to the Waukesha, Wis.-based company.
Q.Freeze combines the quantitative benefits of 4D phase-matched PET/CT imaging, MotionMatch, into one static image, according to the Waukesha, Wis.-based company.
